CDT Equity (CDT) Competitors $1.33 0.00 (0.00%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.75%) As of 09/2/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDT vs. ABP, ATNF, AYTU, FNCH, CYCC, IXHL, HOTH, LSB, MBRX, and SYBXShould you be buying CDT Equity stock or one of its competitors? The main competitors of CDT Equity include Abpro (ABP), 180 Life Sciences (ATNF), Aytu BioPharma (AYTU), Finch Therapeutics Group (FNCH), Cyclacel Pharmaceuticals (CYCC), Incannex Healthcare (IXHL), Hoth Therapeutics (HOTH), LakeShore Biopharma (LSB), Moleculin Biotech (MBRX), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry. CDT Equity vs. Its Competitors Abpro 180 Life Sciences Aytu BioPharma Finch Therapeutics Group Cyclacel Pharmaceuticals Incannex Healthcare Hoth Therapeutics LakeShore Biopharma Moleculin Biotech Synlogic Abpro (NASDAQ:ABP) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Does the media refer more to ABP or CDT? In the previous week, CDT Equity had 1 more articles in the media than Abpro. MarketBeat recorded 1 mentions for CDT Equity and 0 mentions for Abpro. Abpro's average media sentiment score of 1.87 beat CDT Equity's score of 0.29 indicating that Abpro is being referred to more favorably in the media. Company Overall Sentiment Abpro Very Positive CDT Equity Neutral Which has higher valuation and earnings, ABP or CDT? Abpro has higher revenue and earnings than CDT Equity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbpro$183K110.44-$7.23MN/AN/ACDT EquityN/AN/A-$17.80M-$435.000.00 Do analysts recommend ABP or CDT? Abpro currently has a consensus target price of $4.00, suggesting a potential upside of 1,486.67%. Given Abpro's stronger consensus rating and higher possible upside, research analysts clearly believe Abpro is more favorable than CDT Equity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00CDT Equity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals have more ownership in ABP or CDT? 23.3% of Abpro shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 20.8% of Abpro shares are owned by insiders. Comparatively, 7.7% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ABP or CDT more profitable? Company Net Margins Return on Equity Return on Assets AbproN/A N/A -241.16% CDT Equity N/A N/A -350.23% Which has more risk and volatility, ABP or CDT? Abpro has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, CDT Equity has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. SummaryAbpro beats CDT Equity on 9 of the 11 factors compared between the two stocks. Get CDT Equity News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricCDT EquityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.07M$2.51B$5.75B$9.77BDividend YieldN/A48.51%6.66%4.50%P/E Ratio0.0022.6982.5826.39Price / SalesN/A727.88535.42110.55Price / CashN/A26.3325.7028.92Price / Book1.166.8111.196.58Net Income-$17.80M$32.94M$3.28B$265.84M7 Day Performance-6.99%0.08%-0.19%-0.26%1 Month Performance-26.11%7.31%8.36%5.82%1 Year Performance-99.31%0.18%55.89%22.47% CDT Equity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTCDT Equity0.091 of 5 stars$1.33flatN/A-99.3%$4.07MN/A0.003Short Interest ↑ABPAbproN/A$0.25-1.6%$4.00+1,532.0%N/A$19.96M$180K0.0015Positive NewsGap DownATNF180 Life Sciences0.9085 of 5 stars$3.30-31.4%N/A+55.2%$19.93MN/A-0.227Positive NewsHigh Trading VolumeAYTUAytu BioPharma4.086 of 5 stars$2.30+4.5%$10.00+334.8%-6.0%$19.75M$81M-3.19160Positive NewsShort Interest ↓Gap UpFNCHFinch Therapeutics Group0.543 of 5 stars$12.00-11.0%N/A+1.5%$19.27MN/A-1.36190Short Interest ↑Gap UpCYCCCyclacel Pharmaceuticals1.5336 of 5 stars$7.55-5.5%N/A-97.0%$17.89M$40K-0.0114Positive NewsShort Interest ↓IXHLIncannex Healthcare0.4971 of 5 stars$0.74+25.9%N/A-63.8%$17.31M$10K-0.613Short Interest ↓Gap UpHigh Trading VolumeHOTHHoth Therapeutics3.2177 of 5 stars$1.25-3.9%$4.00+220.1%+84.5%$17.24MN/A-1.174News CoverageGap UpLSBLakeShore Biopharma1.3944 of 5 stars$0.82-0.7%N/A-81.4%$17.22M$85.67M0.00773Short Interest ↓Gap UpMBRXMoleculin Biotech2.8821 of 5 stars$0.57+1.3%$4.00+595.9%-85.1%$17.19MN/A0.0020SYBXSynlogic1.0559 of 5 stars$1.48+1.4%N/A-1.4%$17.08M$10K-18.5080Positive News Related Companies and Tools Related Companies Abpro Alternatives 180 Life Sciences Alternatives Aytu BioPharma Alternatives Finch Therapeutics Group Alternatives Cyclacel Pharmaceuticals Alternatives Incannex Healthcare Alternatives Hoth Therapeutics Alternatives LakeShore Biopharma Alternatives Moleculin Biotech Alternatives Synlogic Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDT) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CDT Equity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CDT Equity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
